MiMedx Group, Inc. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
MiMedx Group, Inc. (MDXG) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of $48.58 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-02-25
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-12-31 was $7.44M, a 85.50% decline year-over-year.
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-09-30 was $7.88M, a 10.90% decline year-over-year.
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-06-30 was $17.62M, a 90.48% increase year-over-year.
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2023-12-31 was $51.30M.
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2025 was $48.58M, a 15.67% increase from fiscal 2024.
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2024 was $42.00M, a 32.55% decline from fiscal 2023.
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2023 was $62.26M.
- MiMedx Group, Inc. net income (loss) from continuing operations available to common shareholders, diluted for fiscal 2022 was -$26.53M.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|---|---|
| 2025-12-31 | $48.58M 10-K · filed 2026-02-25 | |||
| 2024-12-31 | $7.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.32M derived: sum of 2 quarters · filed 2026-02-25 | $32.94M derived: sum of 3 quarters · filed 2026-02-25 | $42.00M 10-K · filed 2026-02-25 |
| 2024-09-30 | $7.88M 10-Q · filed 2024-10-30 | $25.50M derived: sum of 2 quarters · filed 2024-10-30 | $34.56M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $17.62M 10-Q · filed 2024-07-31 | $26.68M 10-Q · filed 2024-07-31 | ||
| 2023-12-31 | $51.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $60.14M derived: sum of 2 quarters · filed 2026-02-25 | $69.39M derived: sum of 3 quarters · filed 2026-02-25 | $62.26M 10-K · filed 2026-02-25 |
| 2023-09-30 | $8.84M 10-Q · filed 2024-10-30 | $18.09M derived: sum of 2 quarters · filed 2024-10-30 | $10.97M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $9.25M 10-Q · filed 2024-07-31 | $3.90M 10-Q · filed 2024-07-31 | ||
| 2022-12-31 | -$26.53M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$18.44M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B |